Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

B7-1/CD80 Antibody (IDEC-114 (Galiximab)), mFluor Violet 610 SE, Novus Biologicals™
SDP

Human Monoclonal Antibody

Supplier:  Novus Biologicals NBP281099MFV610

Catalog No. NB283542


Only null left
Add to Cart

Description

Description

B7-1/CD80 Monoclonal antibody specifically detects B7-1/CD80 in Human samples. It is validated for Flow Cytometry
Specifications

Specifications

B7-1/CD80
Monoclonal
mFluor Violet 610 SE
50mM Sodium Borate
Human
Protein A purified
RUO
Primary
Human
Purified
Flow Cytometry
IDEC-114 (Galiximab)
Flow Cytometry
Activation B7-1 antigen, B7, BB1, CD28LG1, CD28LGB7-1 antigen), CD80 antigen, CD80 molecule, costimulatory factor CD80, costimulatory molecule variant IgV-CD80, CTLA-4 counter-receptor B7.1, T-lymphocyte activation antigen CD80
Galiximab was prepared by immunizing cynomolgus monkeys with recombinant B7-1/CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K, 2013)
0.1 mL
Adaptive Immunity, B Cell Development and Differentiation Markers, Cytokine Research, Immunology, Signal Transduction
941
Store at 4C in the dark.
IgG1 λ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.